Taro Pharma (TARO) Misses Q2 EPS by 36c, Approves Special Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Taro Provides Results for September 30, 2018
November 5, 2018 4:05 PM ESTBoard of Directors Approves $500 Million Special Dividend
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the three and six months ended September 30, 2018.
Quarter ended September 30, 2018 Highlights compared to September 30, 2017
Net sales of $159.0 million decreased $10.9 million, the result of continuing increased competition and the challenging pricing environment despite a slight increase in overall volumes. Gross profit of $108.6 million (68.3% of net sales compared to 73.6%) decreased $16.6 million. Research and development (R&D)... More